Oclacitinib 5.4mg Tablets

Oclacitinib 5.4 mg Tablets for Dogs contain oclacitinib, a veterinary medicine belonging to the Janus kinase (JAK) inhibitor class. It helps control itching associated with allergic dermatitis and the clinical signs of atopic dermatitis in dogs.

Oclacitinib works by inhibiting specific pathways involved in inflammatory and allergic responses, helping reduce itching, scratching and associated skin discomfort.

Oclacitinib is the active ingredient in Apoquel 5.4 mg. Apoquel is the reference brand; any product marketed as a generic equivalent should have a verified manufacturer, formulation and applicable veterinary authorization.

This medicine is intended for dogs and should be used only under veterinary supervision.

Product Information

Product Name

Oclacitinib 5.4 mg Tablets

Active Ingredient

Oclacitinib (as oclacitinib maleate)

Strength

5.4 mg per tablet

Dosage Form

Oral tablet; formulation depends on the specific product

Drug Class

Janus kinase (JAK) inhibitor

Therapeutic Category

Veterinary dermatology medicine

Target Species

Dogs

Indications

Itching associated with allergic dermatitis and clinical signs of atopic dermatitis

Reference Brand

Apoquel

Pack Size

Verify actual packaging

Prescription Requirement

Subject to local veterinary medicine regulations

Generic Oclacitinib vs. Apoquel 5.4 mg

Apoquel is a branded veterinary medicine containing oclacitinib. Oclacitinib is the active ingredient, while Apoquel is the reference brand name.

A product containing the same active ingredient and strength should not automatically be assumed to be an approved generic or interchangeable product. Confirm the manufacturer's details, formulation, quality documentation and local veterinary authorization before listing or supplying it as a generic alternative.

Ordering and Availability

For Oclacitinib 5.4 mg tablet pricing, pack sizes and availability, contact the supplier to confirm the exact product, manufacturer, formulation and current stock.

Generic authorization, veterinary prescription requirements and import eligibility vary by country. Verify the applicable regulations before ordering and obtain the medicine through an authorized veterinary pharmacy or eligible supplier.

Oclacitinib 5.4 mg may be prescribed by a veterinarian for:

• Allergic Dermatitis: Helps control itching associated with allergic skin conditions in dogs.
• Atopic Dermatitis: Helps manage the clinical signs of canine atopic dermatitis.
• Itch and Skin Discomfort: May reduce scratching and related discomfort when used as directed.
• Veterinary Treatment Management: Can form part of an individualized treatment plan for selected dogs with allergic skin disease.

Oclacitinib helps control symptoms but does not eliminate every underlying cause of skin disease. Parasites, food allergies, bacterial infections and other skin conditions may require separate diagnosis and treatment.

Give Oclacitinib 5.4 mg Tablets only as directed by a veterinarian. The appropriate dose, frequency and duration depend on the dog's body weight, clinical condition, response to treatment and the approved instructions for the specific product.

Follow the veterinary prescription and product leaflet. Do not change the dose, frequency or treatment duration without professional advice.

Product labeling commonly restricts use to dogs at least 12 months old. Additional weight restrictions and other eligibility criteria may apply, depending on the jurisdiction and product authorization.

Storage Instructions

Store the tablets according to the manufacturer's packaging and official product leaflet. Protect the medicine from unsuitable storage conditions and keep it out of the reach of children and animals.

Follow the product-specific instructions for tablet splitting, storage of unused tablet portions and disposal. Do not use the medicine after its stated expiry date.

Potential adverse effects include:

• Vomiting or diarrhoea
• Reduced appetite
• Lethargy
• Skin or ear infections
• Increased susceptibility to certain infections

Because oclacitinib modulates immune signalling, it may increase susceptibility to infection and may worsen certain neoplastic conditions.

Contact a veterinarian if the dog develops persistent digestive symptoms, unusual lethargy, worsening skin lesions, signs of infection or other unexpected reactions.

Before treatment, inform the veterinarian about the dog's medical history, current medicines, existing infections and any history of tumours.

Important precautions include:

• Age restrictions: Follow the minimum age stated in the applicable product leaflet.
• Immune system effects: Veterinary assessment is important because oclacitinib modulates immune responses.
• Infections: Dogs should be monitored for infections during treatment.
• Neoplastic conditions: Use requires particular caution where tumours or progressive malignant disease are present.
• Pregnancy and breeding: Follow the product-specific restrictions and consult the veterinarian before use in breeding, pregnant or lactating dogs.
• Veterinary supervision: Do not use this medicine without a veterinary assessment.

The precise contraindications and warnings depend on the approved product label. Always check the leaflet supplied with the actual product.